Abstract Search

ey0021.11-4 | Interventions for Weight Loss: New Findings | ESPEYB21

11.4. Setmelanotide for the treatment of acquired hypothalamic obesity: a phase 2, open-label, multicentre trial

CL Roth , C Scimia , AH Shoemaker , M Gottschalk , J Miller , G Yuan , S Malhotra , MJ Abuzzahab

Brief Summary: This phase 2, open-label, multicenter trial examined the efficacy of setmelanotide, a melanocortin-4 receptor agonist, in patients aged 6 to 40 years with obesity due to hypothalamic injury. Setmelanotide reduced body mass index (BMI) and hunger levels in most participants; 89% achieved a reduction in BMI of at least 5% after 16 weeks. These results indicate that setmelanotide is a promising treatment for hypothalamic obesity.This phase 2 ...

0 shares

ey0020.10-2 | New Data on the Epidemiology of T2D in Children | ESPEYB20

10.2. The Coronavirus Disease 2019 pandemic is associated with a substantial rise in frequency and severity of presentation of youth-onset type 2 diabetes

SN Magge , RM Wolf , L Pyle , EA Brown , VC Benavides , ME Bianco , LC Chao , A Cymbaluk , PG Balikcioglu , K Halpin , DS Hsia , L Huerta-Saenz , JJ Kim , S Kumar , LE Levitt--Katz , BE Marks , A Neyman , KL O'Sullivan , SS Pillai , AS Shah , AH Shoemaker , JAW Siddiqui , S Srinivasan , IH Thomas , JB Tryggestad , MF Yousif , MM Kelsey , COVID-19 and Type 2 Diabetes Consortium Kelsey

Brief summary: A significant increase in the incidence T2D occurred in the USA during the COVID-19 pandemic, particularly among children with obesity and males.Comment: This is the first multicenter report on the incidence of T2D during the first year of the COVID-19 pandemic in the USA. The average number of new diagnoses per year in the two pre-pandemic years was 825, compared with 1463 during the first pandemic year. This increase of 77% is significan...

0 shares

ESPE Yearbook of Paediatric Endocrinology

11.4. Setmelanotide for the treatment of acquired hypothalamic obesity: a phase 2, open-label, multicentre trial

10.2. The Coronavirus Disease 2019 pandemic is associated with a substantial rise in frequency and severity of presentation of youth-onset type 2 diabetes

BiosciAbstracts